ITMI920591A1 - Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson - Google Patents

Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson

Info

Publication number
ITMI920591A1
ITMI920591A1 IT000591A ITMI920591A ITMI920591A1 IT MI920591 A1 ITMI920591 A1 IT MI920591A1 IT 000591 A IT000591 A IT 000591A IT MI920591 A ITMI920591 A IT MI920591A IT MI920591 A1 ITMI920591 A1 IT MI920591A1
Authority
IT
Italy
Prior art keywords
treatment
pharmaceutical compositions
compositions including
parkinson disease
derivatives suitable
Prior art date
Application number
IT000591A
Other languages
English (en)
Inventor
Skaper Drake
Aurelio Romeo
Gino Toffano
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Spa filed Critical Fidia Spa
Publication of ITMI920591A0 publication Critical patent/ITMI920591A0/it
Priority to ITMI920591A priority Critical patent/IT1254280B/it
Priority to AU37477/93A priority patent/AU3747793A/en
Priority to PCT/EP1993/000571 priority patent/WO1993017691A2/en
Priority to AT96116051T priority patent/ATE206053T1/de
Priority to DE69330842T priority patent/DE69330842T2/de
Priority to JP5515350A priority patent/JP2872809B2/ja
Priority to EP96116051A priority patent/EP0770389B1/en
Priority to ES96116051T priority patent/ES2161953T3/es
Priority to EP93906509A priority patent/EP0630250A1/en
Publication of ITMI920591A1 publication Critical patent/ITMI920591A1/it
Priority to US08/304,391 priority patent/US6620792B1/en
Application granted granted Critical
Publication of IT1254280B publication Critical patent/IT1254280B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITMI920591A 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson IT1254280B (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ITMI920591A IT1254280B (it) 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
DE69330842T DE69330842T2 (de) 1992-03-13 1993-03-12 Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration
PCT/EP1993/000571 WO1993017691A2 (en) 1992-03-13 1993-03-12 Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
AT96116051T ATE206053T1 (de) 1992-03-13 1993-03-12 Verwendung von monosialogangliosid gml oder von n-dichlor-acetyl-lyso-gml zur vorbeugung oder zur umkehrung der von einer langzeitbehandlung mit l- dopa bei der therapie von morbus parkinson induzierten neuronale degeneration
AU37477/93A AU3747793A (en) 1992-03-13 1993-03-12 Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
JP5515350A JP2872809B2 (ja) 1992-03-13 1993-03-12 モノシアロガングリオシドｇｍ▲下１▼またはその誘導体を含有する，パーキンソン病の治療に適する医薬組成物
EP96116051A EP0770389B1 (en) 1992-03-13 1993-03-12 Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease
ES96116051T ES2161953T3 (es) 1992-03-13 1993-03-12 Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson.
EP93906509A EP0630250A1 (en) 1992-03-13 1993-03-12 Pharmaceutical compositions containing monosialoganglioside gm 1? or a derivative thereof suitable for the treatment of parkinson's disease
US08/304,391 US6620792B1 (en) 1992-03-13 1994-09-12 Pharmaceutical compositions containing monosialoganglioside GM1 or derivative thereof suitable for the treatment of parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI920591A IT1254280B (it) 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson

Publications (3)

Publication Number Publication Date
ITMI920591A0 ITMI920591A0 (it) 1992-03-13
ITMI920591A1 true ITMI920591A1 (it) 1993-09-13
IT1254280B IT1254280B (it) 1995-09-14

Family

ID=11362423

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI920591A IT1254280B (it) 1992-03-13 1992-03-13 Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson

Country Status (8)

Country Link
US (1) US6620792B1 (it)
EP (2) EP0770389B1 (it)
JP (1) JP2872809B2 (it)
AT (1) ATE206053T1 (it)
DE (1) DE69330842T2 (it)
ES (1) ES2161953T3 (it)
IT (1) IT1254280B (it)
WO (1) WO1993017691A2 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1259176B (it) * 1992-10-23 1996-03-11 Fidia Spa Composizioni farmaceutiche comprendenti monosialoganglioside gm1 (o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso
JP2005527467A (ja) * 2001-08-29 2005-09-15 ネオーズ テクノロジーズ， インコーポレイテッド 新規な合成ガングリオシド誘導体およびその組成物
EP1367395A1 (de) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
US7943750B2 (en) 2007-06-18 2011-05-17 Laboratoire Medidom S.A. Process for obtaining pure monosialoganglioside GM1 for medical use
CN101732331B (zh) * 2008-11-20 2012-05-23 北京四环制药有限公司 一种单唾液酸四己糖神经节苷脂钠与谷氨酸的组合物
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CN104490837A (zh) * 2014-12-30 2015-04-08 哈尔滨医科大学科技开发总公司 单唾液酸四己糖神经节苷脂钠的口服制剂
RU2632710C2 (ru) * 2016-03-31 2017-10-09 Лонг Шенг Фарма Лимитед Способ получения натрий моносиалового ганглиозида и нейропротекторное средство на его основе
CN108815131B (zh) * 2018-09-11 2021-01-01 四川奇格曼药业有限公司 一种神经节苷脂缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1199116B (it) * 1984-07-03 1988-12-30 Fidia Farmaceutici Derivati di gangliosidi
IT1208751B (it) * 1986-06-30 1989-07-10 Fidia Farmaceutici Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali
IT1235161B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisogangliosidi
IT1249034B (it) * 1990-06-29 1995-02-11 Fidia Spa Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi
IT1253832B (it) * 1991-08-01 1995-08-29 Fidia Spa Derivati di gangliosidi

Also Published As

Publication number Publication date
DE69330842T2 (de) 2002-04-04
EP0770389B1 (en) 2001-09-26
WO1993017691A2 (en) 1993-09-16
ES2161953T3 (es) 2001-12-16
JPH07508258A (ja) 1995-09-14
US6620792B1 (en) 2003-09-16
EP0770389A1 (en) 1997-05-02
DE69330842D1 (de) 2001-10-31
EP0630250A1 (en) 1994-12-28
JP2872809B2 (ja) 1999-03-24
ATE206053T1 (de) 2001-10-15
IT1254280B (it) 1995-09-14
ITMI920591A0 (it) 1992-03-13
WO1993017691A3 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
DE69937198D1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
IT8720698A0 (it) Composizione farmaceutica adattivita' terapeutica per il trattamento della demenza senile di tipo alzheimer.
DK0664708T3 (da) Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe
ITMI920591A1 (it) Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
BR0116481A (pt) Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
ES2052732T3 (es) 2',3'-didesoxi-3'-fluorotimidina y compuestos afines para el tratamiento de infecciones por adenovirus.
DK0628548T3 (da) 1,2,3,4-Tetraydro-acridinamin-derivater
IL73292A0 (en) Kit for administering gangliosides and derivatives thereof by inhalation and pharmaceutical composition suitable therefor
ES2134313T3 (es) Utilizacion de derivados de pregnano para el tratamiento de tumores.
IT8920358A0 (it) Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
ATE69381T1 (de) Anwendung exogener ganglioside zur herstellung eines arzneimittels zur anwendung bei tumorkrankheiten als schutzmittel gegen die toxizitaet tumorhemmender arzneimittel.
PT90816A (pt) Processo para a preparacao de composicoes farmaceuticas contendo analogos de 2',5'-oligoadenilato
ATE120447T1 (de) Polyamin-derivate als antineoplastische mittel.
DE3175733D1 (en) An orally administered drug form comprising a glycosidic antibiotic and an adjuvant
FI913699A0 (fi) Menetelmä farmaseuttisesti käyttökelpoisten 4'-epi-4'-aminoantrasykliinien valmistamiseksi sekä menetelmässä käytettävät välituotteet
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
IT1204764B (it) Utilizzazione terapeutica del fruttosio-1,6-difosfato per la protezione nei confronti della tossicita' indotta da somministrazione di antitumorali antraciclinici
IT1236584B (it) Uso di gangliosidi nel trattamento della disfunzione autonomica nel morbo di chagas
IT8322949A0 (it) Composizione farmaceutica utile per il miglioramento e/o il trattamento di sintomi mentali provocati da disturbi organici nel cervello.
IT1231944B (it) Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoilderivato della d-carnitina
ITPD920189A0 (it) Nuove composizioni farmaceutiche comprendenti monosialoganglioside gm1(o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso
ITPD920190A1 (it) Composizioni farmaceutiche comprendenti gangliosidi o derivati gangliosidici atte al trattamento di condizioni patologiche caratte-
ITMI920106A1 (it) Composizioni farmaceutiche comprendenti melatonina o un suo derivato-agonista, atte al trattamento dei disordini cerebro-vascolari
AU3747793A (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease